Johnson & Johnson (NYSE:JNJ) Stock Position Lifted by Garrison Point Advisors LLC

Garrison Point Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 17.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 18,661 shares of the company's stock after purchasing an additional 2,715 shares during the period. Johnson & Johnson makes up about 1.3% of Garrison Point Advisors LLC's portfolio, making the stock its 16th biggest position. Garrison Point Advisors LLC's holdings in Johnson & Johnson were worth $2,699,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Norges Bank acquired a new position in shares of Johnson & Johnson in the fourth quarter worth about $4,390,037,000. Raymond James Financial Inc. acquired a new position in Johnson & Johnson in the 4th quarter worth about $1,339,878,000. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after purchasing an additional 1,772,706 shares during the period. Franklin Resources Inc. lifted its position in shares of Johnson & Johnson by 11.4% during the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock valued at $2,721,355,000 after buying an additional 1,729,281 shares in the last quarter. Finally, Amundi increased its holdings in Johnson & Johnson by 16.2% in the 4th quarter. Amundi now owns 11,930,183 shares of the company's stock worth $1,698,984,000 after acquiring an additional 1,660,458 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Remove Ads

Insider Buying and Selling

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on JNJ shares. Wells Fargo & Company reduced their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Morgan Stanley raised their price target on shares of Johnson & Johnson from $163.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Wednesday. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Leerink Partners lowered their target price on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eight investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $171.67.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $2.29 during trading on Thursday, reaching $148.68. The company's stock had a trading volume of 7,778,407 shares, compared to its average volume of 7,916,323. The business has a 50 day moving average price of $159.50 and a 200-day moving average price of $155.37. The company has a market capitalization of $358.29 billion, a P/E ratio of 22.30, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. During the same quarter in the previous year, the company earned $2.29 EPS. The company's quarterly revenue was up 5.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.